Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • COVID-19
    • Safety
    • Drug Reference Sheet
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    When the Provider Becomes the Patient: What I Learned From COVID-19
    COVID-19
    When the Provider Becomes the Patient: What I Learned From COVID-19
    June 24, 2022
    The Case of the Late Head and Neck Lymphedema
    Clinical practice
    The Case of the Late Head and Neck Lymphedema
    June 20, 2022
    Our Patients Give Us Peace in Unexpected Circumstances
    Oncology nurse pride
    Our Patients Give Us Peace in Unexpected Circumstances
    June 17, 2022
    Behind Our Masks, I See You, I Hear You
    COVID-19
    Behind Our Masks, I See You, I Hear You
    June 10, 2022
    Connect With Your Patients on a Human Level as Well as a Healthcare Level
    Oncology nurse-patient relationship
    Connect With Your Patients on a Human Level as Well as a Healthcare Level
    June 03, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Cancer treatments

    CAR T-Cell Therapy Programs
    Cancer treatments

    CAR T-Cell Therapy Programs

    Debuting in human clinical trials just a decade ago, chimeric antigen receptor (CAR) T-cell therapy was quickly hailed as a breakthrough cancer treatment for certain hematologic cancers. Today, patients and providers have access to 22 U.S. Food and Drug Administration (FDA)–approved cellular and gene therapy products, and CAR T-cell therapy is available beyond large academic research centers.

    May 03, 2022
    Fiber—but Not Probiotics—Boosts Immunotherapy Response for Melanoma
    Immunotherapy

    Fiber—but Not Probiotics—Boosts Immunotherapy Response for Melanoma

    Patients with melanoma who consume a high-fiber diet during treatment with immune checkpoint inhibitors (ICIs) or anti-PD-1 therapy experience longer progression-free survival than those who don’t, researchers reported in Science. And probiotic supplementation, often considered a healthy behavior, reduces immunotherapy response.

    March 23, 2022
    Nursing Considerations for ICI-Related Myocarditis
    Cancer research

    Nursing Considerations for ICI-Related Myocarditis

    Before immunotherapies like immune checkpoint inhibitors (ICIs) became a cancer treatment option, myocarditis typically developed in the presence of infections, drug allergies, or autoimmune diseases. Activating the immune system with ICIs can also trigger autoimmune-like adverse events such as myocarditis, and although its incidence in patients with cancer is low, mortality is high.

    March 08, 2022
    ONS Launches New Learning Extension Activities for Popular Cancer Basics Course
    Press Releases

    ONS Launches New Learning Extension Activities for Popular Cancer Basics Course

    The Oncology Nursing Society’s (ONS’s) new Learning Extension Activities Plan (LEAP), an opportunity for student nurse learners to further develop their knowledge of some of the topics covered in ONS’s Cancer Basics course, was created to help faculty members teach oncology to nursing students.

    March 02, 2022
    How Liquid Biopsies Are Used in Cancer Treatment Selection
    Cancer treatments

    How Liquid Biopsies Are Used in Cancer Treatment Selection

    Biomarker testing is an essential tool when choosing the right treatment for many advanced solid cancers. However, tissue-based testing may take weeks to get results with a chance that not enough tissue was collected to complete the entire biomarker panel. Blood draw–based liquid biopsies may be a useful alternative to identify a tumor’s biomarker details and can be performed by testing for circulating tumor DNA (ctDNA).

    February 03, 2022
    Today’s Immunotherapy Combinations
    Immunotherapy

    Today’s Immunotherapy Combinations

    Immunotherapy has revolutionized cancer treatment, especially for patients with diseases considered otherwise incurable. Since May 2017, the U.S. Food and Drug Administration (FDA) has approved 27 immunotherapy combinations, including chemoimmunotherapy and regimens with targeted therapies, and researchers are reporting highly promising data from clinical trials of its combination with radiation.

    February 01, 2022
    Cancer Cells’ Aneuploidy May Be Why They Resist Treatment
    Cancer research

    Cancer Cells’ Aneuploidy May Be Why They Resist Treatment

    The extra or missing chromosomes—also called aneuploidy—in 90% of cancer cells may be a factor in treatment resistance, a new study shows. Researchers reported the findings in Developmental Cell.

    January 19, 2022
    FDA Approves Rituximab Plus Chemotherapy for Pediatric Cancer Indications
    U.S. Food and Drug Administration (FDA)

    FDA Approves Rituximab Plus Chemotherapy for Pediatric Cancer Indications

    On December 2, 2021, the U.S. Food and Drug Administration (FDA) approved rituximab (Rituxan®) in combination with chemotherapy for pediatric patients aged at least 6 months to 18 years with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia. 

    December 03, 2021
    What Is a Liquid Biopsy?
    Clinical practice

    What Is a Liquid Biopsy?

    All cells (healthy cells and tumor cells) in the body shed DNA, called cell-free DNA (cfDNA). When it’s only from tumor cells, it’s referred to as circulating tumor DNA (ctDNA), although cfDNA and ctDNA are sometimes used interchangeably.

    October 25, 2021
    FDA Approves Cabozantinib for Differentiated Thyroid Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Cabozantinib for Differentiated Thyroid Cancer

    On September 17, 2021, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx®) for adult and pediatric patients aged 12 years and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor (VEGFR)-targeted therapy and who are ineligible for or refractory to radioactive iodine treatment.

    September 22, 2021
    The Case of the Triple-Negative Breast Cancer Targeted Treatment
    Breast cancer

    The Case of the Triple-Negative Breast Cancer Targeted Treatment

    Ophelia is a 42-year-old patient who has been diagnosed with triple-negative breast cancer (TNBC). She completed neoadjuvant chemotherapy with dose-dense doxorubicin and cyclophosphamide, followed by paclitaxel and carboplatin. Her postsurgical pathology shows residual disease in the tumor (3.5 cm down from 4 cm) and 12 out of 18 lymph nodes that are positive for cancer. Ophelia tells you that she is very discouraged and expected a better treatment outcome.

    September 21, 2021
    Testicular Cancer Treatment and Survival Rates Are Improving
    Cancer research

    Testicular Cancer Treatment and Survival Rates Are Improving

    Progression-free and overall survival rates for patients with metastatic testicular cancer have significantly grown since 1990, researchers reported in the Journal of Clinical Oncology.

    August 25, 2021
    Scientists Identify Protein Implicated in Tumor Growth, Treatment Resistance
    Cancer research

    Scientists Identify Protein Implicated in Tumor Growth, Treatment Resistance

    A protein called AMBRA1 may be to blame for tumor resistance to CDK4/6 inhibitors, according to results from international teams of researchers that were reported in Nature.

    July 21, 2021
    Oncology Drug Reference Sheet: Tepotinib
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Tepotinib

    Tepotinib (Tepmetko®) was granted accelerated approval in February 2021 for mesenchymalepithelial transition (MET)-altered metastatic non-small cell lung cancer (NSCLC) based on overall response rate and duration. The drug is still under long-term evaluation and healthcare providers should report all serious adverse events that may be associated to FDA’s MedWatch Reporting System.

    June 22, 2021
    Imaging Test Identifies Treatment Choices for ER-Positive Breast Cancer
    Research

    Imaging Test Identifies Treatment Choices for ER-Positive Breast Cancer

    Using positron-emission tomography with a radioactive tracer identifies levels of progesterone receptor in patients with estrogen receptor-positive breast cancer, researchers reported in Nature Communications. The diagnostic tool would help clinicians determine which patients are most likely to respond to hormone therapies for breast cancer.

    May 27, 2021
    Oncology Drug Reference Sheet: Trilaciclib
    Clinical practice

    Oncology Drug Reference Sheet: Trilaciclib

    On February 12, 2021, the U.S. Food and Drug Administration approved trilaciclib (CoselaTM), a parenteral inhibitor of cyclin-dependent kinase, to prevent myelosuppression when administered prior to chemotherapy administration. The approval is currently limited to the use of trilaciclib before treatment with platinum- and etoposide-containing regimens and topotecan-containing regimens for treatment of extensive-stage small cell lung cancer.

    May 25, 2021
    FDA Approves Nivolumab for Resected Esophageal or GEJ Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Nivolumab for Resected Esophageal or GEJ Cancer

    On May 20, 2021, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo®) for patients with completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease who have received neoadjuvant chemoradiotherapy.

    May 21, 2021
    Targeted Therapies Are Transforming the Treatment of Non-Small Cell Lung Cancer
    Lung Cancer

    Targeted Therapies Are Transforming the Treatment of Non-Small Cell Lung Cancer

    Testing for molecular biomarkers has become a mainstay in determining treatment approaches for advanced-stage non-small cell lung cancer. Typically, next-generation sequencing identifies any potential genomic variants that are associated with oncogenic driver events and can be targeted with oral tyrosine kinase inhibitors.

    May 17, 2021
    Larotrectinib and Other Tumor-Agnostic Targeted Therapies Are Leading Cancer Care Into the Next Frontier
    Targeted therapy

    Larotrectinib and Other Tumor-Agnostic Targeted Therapies Are Leading Cancer Care Into the Next Frontier

    In 2018, the cancer drug larotrectinib quietly became a milestone along the evolving path to approaching cancer therapy: it was the first agent approved to treat a genetic variant, not a specific type of cancer or disease site. And as oncology treatment science progresses, many predict that it won’t be the last—it’s already been joined by pembrolizumab and entrectinib as tumor-agnostic therapies. The key to curing cancer may be hidden in the disease’s genetic code rather than its location in the body.

    May 11, 2021
    ONS Congress

    The Horizon Looks Promising for Emerging Radiation Therapies in Oncology Care

    Cutting-edge advancements in radiation therapy (RT) may allow oncology practitioners to only target the current tumor and avoid damaging healthy tissue. During a session on April 29, 2021, at the ONS 46th Annual Congress, W. Neil Duggar, PhD, DABR, of the University of Mississippi Medical Center, provided an overview of RT from a medical physics perspective, with a focus on how developing technologies may revolutionize care for patients with cancer. 

    April 29, 2021
    ONS Congress

    Radiopharmaceuticals Pack a One-Two Punch Against Cancer

    Radionuclides, also called radioisotopes, are unstable chemical elements that release radiation as they break down, and that action can be combined with cancer drugs to fight tumors with a new punch. During a session on April 27, 2021, for the 46th Annual ONS Congress, Pam Grubbs, APRN, CNS, MS, AOCNS®, of Mayo Clinic in Rochester, MN, discussed how oncology is using radiopharmaceuticals in a variety of ways.

    April 27, 2021
    FDA Grants Accelerated Approval to Loncastuximab Tesirine-Lpyl for Large B-Cell Lymphoma
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Loncastuximab Tesirine-Lpyl for Large B-Cell Lymphoma

    On April 23, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta™), a CD19-directed antibody and alkylating agent conjugate, for adult patients with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma, after two or more lines of systemic therapy.

    April 26, 2021
    ONS Congress

    Oncology Nurses Navigate the Changing Landscape of Immuno-Oncology

    Immune checkpoint inhibitors (ICPIs) enhance treatment response while minimizing toxicities for patients with cancer. However, education is key to managing the therapies’ unique adverse events (AEs). During a session for the ONS 46th Annual Congress™, Marianne Davies, DNP, ACNP, FAAN, of the Yale Comprehensive Cancer Center, Smilow Cancer Hospital at Yale New Haven Hospital, and the Yale University School of Nursing, and Laura S. Wood, RN, MSN, OCN®, of Cleveland Clinic Cancer Center, provided oncology nurses with a foundation for evaluating and grading AEs in immuno-oncology.

    April 22, 2021
    ONS Congress

    Building a CAR T-Cell Program: How to Go From None to Done

    Chimeric antigen receptor (CAR) T-cell therapy is a promising new treatment option for patients with certain types of cancer. As the field expands, institutions are exploring specialized service lines to provide the treatment, speakers said during a presentation on April 22, 2021, for the 46th Annual ONS Congress™ as they shared the lessons learned as their institutions established CAR T-cell therapy programs.

    April 22, 2021
    FDA Approves Nivolumab in Combination With Chemotherapy for Metastatic Gastric Cancer and Esophageal Adenocarcinoma
    Clinical practice

    FDA Approves Nivolumab in Combination With Chemotherapy for Metastatic Gastric Cancer and Esophageal Adenocarcinoma

    On April 16, 2021, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo®) in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

    April 19, 2021
    Oncology Drug Reference Sheet: Decitabine and Cedazuridine
    Cancer treatments

    Oncology Drug Reference Sheet: Decitabine and Cedazuridine

    In July 2020, the U.S. Food and Drug Administration approved decitabine and cedazuridine (Inqovi®) tablets for the treatment of adults with myelodysplastic syndromes. 

    March 30, 2021
    The Case of the Sensitive Staging System
    Survivorship care plans

    The Case of the Sensitive Staging System

    Marianne, an oncology nurse navigator, is preparing a cancer treatment summary and survivorship care plan for Sylvia, who finished breast cancer treatment six weeks ago. Sylvia was treated with neoadjuvant therapy followed by mastectomy, reconstruction, and radiation. Her tumor was characterized as multifocal invasive ductal carcinoma, grade 2, estrogen and progesterone positive, and HER2/neu negative. Sylvia has no family history of breast cancer. Marianne notices that the oncologist recorded Sylvia’s cancer as a stage IB. Marianne wonders if the stage was determined before or after chemotherapy and surgery.

    February 15, 2021
    FDA Approves Cemiplimab-Rwlc for Locally Advanced and Metastatic Basal Cell Carcinoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Cemiplimab-Rwlc for Locally Advanced and Metastatic Basal Cell Carcinoma

    On February 9, 2021, the U.S. Food and Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo®) for use in patients with locally advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate. FDA also granted accelerated approval to cemiplimab-rwlc for patients with metastatic BCC previously treated with an HHI or for whom an HHI is not appropriate. 

    February 10, 2021
    FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Large B-Cell Lymphoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Large B-Cell Lymphoma

    On February 5, 2021, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (Breyanzi®) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma not otherwise specified—including DLBCL arising from indolent lymphoma—high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.

    February 10, 2021
    FDA Grants Accelerated Approval to Umbralisib for Marginal Zone and Follicular Lymphoma
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Umbralisib for Marginal Zone and Follicular Lymphoma

    On February 5, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to umbralisib (Ukoniq™), a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon, for adult patients with relapsed or refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and adult patients with relapsed or refractory follicular lymphoma who have received at least three prior lines of systemic therapy.

    February 08, 2021
    FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC

    On February 3, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tepotinib (Tepmetko®) for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition exon 14 skipping alterations.

    February 03, 2021
    Oncology Drug Reference Sheet: Tafasitamab-Cxix
    Oncology drug research

    Oncology Drug Reference Sheet: Tafasitamab-Cxix

    Tafasitamab-cxix (Monjuvi®) received accelerated approval from the U.S. Food and Drug Administration in July 2020 in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma.

    January 26, 2021
    FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma
    Cancer treatments

    FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma

    On January 22, 2021, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) as first-line treatment for patients with advanced renal cell carcinoma.

    January 25, 2021
    FDA Approves Fam-Trastuzumab Deruxtecan-Dxki for HER2-Positive Gastric Adenocarcinomas
    Cancer treatments

    FDA Approves Fam-Trastuzumab Deruxtecan-Dxki for HER2-Positive Gastric Adenocarcinomas

    On January 15, 2021, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu®) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

    January 19, 2021
    FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory, Systemic ALK-Positive Anaplastic Large Cell Lymphoma
    Cancer treatments

    FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory, Systemic ALK-Positive Anaplastic Large Cell Lymphoma

    On January 14, 2021, the U.S. Food and Drug Administration (FDA) approved crizotinib (Xalkori®) for pediatric patients aged one year or older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK) positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL. 

    January 15, 2021
    Genomics Provides Insight on Exceptionally Responding Patients
    Genetics & genomics

    Genomics Provides Insight on Exceptionally Responding Patients

    Patients with cancer who experience unexpected and long-lasting treatment outcomes are considered exceptional responders, but researchers and clinicians had no insight as to why the patients did so well with treatment. Results of a new study now show that genomic characterizations of cancer can uncover genetic alterations that may contribute to the phenomenon, researchers reported in Cancer Cell.

    January 13, 2021
    Adding Nivolumab to Chemo Improves Survival for Advanced Gastric Cancer
    Chemotherapy

    Adding Nivolumab to Chemo Improves Survival for Advanced Gastric Cancer

    First-line therapy combining nivolumab with chemotherapy improved median overall survival rates in patients with PD-L1-expressing gastric cancer by 3.3 months in a large international, multicenter trial. The findings were reported during the 2020 European Society for Medical Oncology virtual meeting.

    December 30, 2020
    Oncology Drug Reference Sheet: Alpelisib
    Clinical practice

    Oncology Drug Reference Sheet: Alpelisib

    When used in combination with fulvestrant, alpelisib (Piqray®) produced complete or partial responses in 29% of patients with PIK3CA-altered, estrogen receptor-positive advanced breast cancer in clinical trials. The U.S. Food and Drug Administration approved it for use in 2019.

    December 29, 2020
    Genomics May Trick PARP Inhibitors to Treat More Cancers
    Research

    Genomics May Trick PARP Inhibitors to Treat More Cancers

    Turning on the body’s inflammasome with epigenetic therapy may improve the efficacy of PARP inhibitors across multiple tumor types, possibly expanding the therapy’s application to new cancers, researchers reported in Proceedings of the National Academy of Sciences.

    December 23, 2020
    FDA Approves Selinexor for Relapsed or Refectory Multiple Myeloma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Selinexor for Relapsed or Refectory Multiple Myeloma

    On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved selinexor (Xpovio®) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refectory multiple myeloma who have received at least one prior therapy. 

    December 21, 2020
    FDA Approves Relugolix for Advanced Prostate Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Relugolix for Advanced Prostate Cancer

    On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved the first oral gonadotropin-releasing hormone receptor antagonist, relugolix, (Orgovyx™) for adult patients with advanced prostate cancer. 

    December 21, 2020
    FDA Approves Margetuximab-cmkb for Metastatic HER2-Positive Breast Cancer
    Cancer treatments

    FDA Approves Margetuximab-cmkb for Metastatic HER2-Positive Breast Cancer

    On December 16, 2020, the U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb (Margenza™) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who previously received two or more anti-HER2 regimens, at least one of which was for metastatic disease.

    December 18, 2020
    Pancreatic Cancer Risk Factors, Diagnosis, Treatment, Side Effects, and Survivorship Considerations
    Pancreatic cancer

    Pancreatic Cancer Risk Factors, Diagnosis, Treatment, Side Effects, and Survivorship Considerations

    Pancreatic cancer is the ninth most common cancer in the United States, accounting for 3% of all cancers but causing 7% of cancer-related deaths, which equates to about 57,500 diagnoses and 47,050 deaths each year. The average person’s risk for pancreatic cancer is about 1 in 64.

    December 03, 2020
    FDA Approves Pralsetinib for RET-Altered Thyroid Cancers
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pralsetinib for RET-Altered Thyroid Cancers

    On December 1, 2020, the U.S. Food and Drug Administration (FDA) approved pralsetinib for patients aged 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy or RET fusion-positive therapy and who are refractory to radioactive iodine (if radioactive iodine is appropriate).

    December 02, 2020
    NKT Cells May Be the Next Wave of CAR Therapy
    Research

    NKT Cells May Be the Next Wave of CAR Therapy

    When genetically modified with a chimeric antigen receptor (CAR), natural killer T (NKT) cells eliminated 50% of metastases in a patient with heavily pretreated, relapsed or refractory metastatic neuroblastoma, according to interim findings from an ongoing study that were published in Nature Medicine.

    December 02, 2020
    FDA Grants Accelerated Approval to Naxitamab for High-Risk Neuroblastoma in Bone or Bone Marrow
    Clinical practice

    FDA Grants Accelerated Approval to Naxitamab for High-Risk Neuroblastoma in Bone or Bone Marrow

    On November 25, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to naxitamab (Danyelza®) in combination with granulocyte-macrophage colony-stimulating factor for pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who demonstrate a partial response, minor response, or stable disease to prior therapy.

    November 30, 2020
    The Evolving Landscape of Cell Transplant Therapy in Cancer Care
    Cancer treatments

    The Evolving Landscape of Cell Transplant Therapy in Cancer Care

    Each year more than 50,000 stem cell transplantations are completed worldwide. The stimulation, harvesting, and therapeutic use of patient and donor cells has evolved as a treatment for diverse cancer diagnoses, and specially trained nurses are at the heart of the clinical trials and care delivery to propel cell transplant therapy across practice settings.

    October 29, 2020
    It’s Time to Take a New Look at Radiation Therapy
    Radiation therapy

    It’s Time to Take a New Look at Radiation Therapy

    Radiation therapy (RT) has been used as a safe and effective treatment option for patients with cancer for more than a century. Like any cancer therapy, it does carry risks and side effects, but RT has improved drastically over the past 20 years and has even been shown to enhance the effectiveness of immunotherapy.

    October 07, 2020
    New Treatments in Radiation Oncology
    Radiation therapy

    New Treatments in Radiation Oncology

    Included in the treatment plan for approximately 50% of all patients with cancer, radiotherapy (RT) is a significant component of cancer care. RT is a technology-driven oncology modality, which means it has continually evolved since being introduced in cancer care in the early 20th century.

    October 06, 2020
    FDA Approves Nivolumab and Ipilimumab for Malignant Pleural Mesothelioma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Nivolumab and Ipilimumab for Malignant Pleural Mesothelioma

    On October 2, 2020, the U.S. Food and Drug Administration (FDA) approved nivolumab in combination with ipilimumab for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery. This is the first drug regimen approved for mesothelioma in 16 years and the second FDA-approved systemic therapy for mesothelioma. 

    October 05, 2020
    • Current page 1
    • Page 2
    • Page 3
    • Next page
    • Last page Last »
    Trending Topics
    • Treatments
    • Research
    • COVID-19
    • Safety
    • Drug Reference Sheet
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Cancer research
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2022 Oncology Nursing Society
     
    Back to Top ▲